Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA)
Key Highlights
- ➤Pliant Therapeutics appointed Craig Blanchette, Ph.D., senior vice president, research (siRNA)
- ➤Blanchette brings more than two decades of RNAi, oligonucleotide chemistry, and delivery expertise
- ➤At Switch Therapeutics, Blanchette advanced two programs into IND-enabling studies
- ➤Pliant granted Blanchette options to purchase 300,000 shares
- ➤Options vest over four years, with 25% vesting after one year
Expert Statements
Bernard Coulie, President and Chief Executive Officer of Pliant Therapeutics
“I am excited to welcome Craig to the team and to see his contributions in realizing the potential of our proprietary integrin-mediated delivery platform”
Bernard Coulie, President and Chief Executive Officer of Pliant Therapeutics
“Craig’s experience in advancing novel delivery platforms and leading siRNA programs from discovery to clinical development will significantly augment Pliant’s deep integrin chemistry and biology expertise.”
Craig Blanchette, Senior Vice President, Research (siRNA) of Pliant Therapeutics
“I am thrilled to join Plaint at such a pivotal moment”
Craig Blanchette, Senior Vice President, Research (siRNA) of Pliant Therapeutics
“The integrin-targeting small molecule discovery platform Pliant has built over the past decade holds immense promise for delivering RNAi to high-value tissues and realizing its full potential for patients with diseases of high unmet need.”
Recognized leader in RNAi drug discovery with track record of advancing novel delivery platforms and therapeutics to drive Company’s integrin-mediated delivery platform
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the appointment of Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA). Dr. Blanchette is an accomplished biopharmaceutical research and development executive with more than two decades of drug discovery and development expertise, including a deep proficiency in RNAi and oligonucleotide chemistry, as well as delivery.
Get started
Create a free account to read the full story.